1-7 of 7
Zhiqiang Sun
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients with Newly Diagnosed Multiple Myeloma (NDMM): Insights from a Multi-Center Study

Dong Liang, Demei Feng, Qiaoli Wang, Shenrui Bai, Min Zeng, Bo Lu, Xiaoqing Li, Zhiqiang Sun, Jianyun Li, Huanhuan Zhou, Jialu Zhang, Xiaoqin Chen, Zhongjun Xia, Yang Liang, Hua Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 7064.
https://doi.org/10.1182/blood-2024-204519
Published: 2024
Journal Articles

Poor Response of Venetoclax/Azacitidine in Monocytic-like Acute Myeloid Leukemia Might be Associated with Genetic Patterns and Could be Improved By Addition of Homoharringtonine

Guopan Yu, Yishan Chen, Zhao Yin, Yu Zhang, Weihua Zhao, Guangyang Weng, Xin Du, Danian Nie, Ziwen Guo, Zhiqiang Sun, Hongyu Zhang, Dongjun Lin, Xinquan Liang, Pengcheng Shi, Xuejie Jiang, Dan Xu, Li Xuan, Baohong Ping, Qifa Liu
Journal: Blood
Blood (2024) 144 (Supplement 1): 1516.
https://doi.org/10.1182/blood-2024-201974
Published: 2024
Journal Articles

The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study

Guopan Yu, Zurong Yao, Zhao Yin, Yu Zhang, Weihua Zhao, Guangyang Weng, Ziwen Guo, Zhiqiang Sun, Pengcheng Shi, Xuejie Jiang, Dan Xu, Li Xuan, Qifa Liu
Journal: Blood
Blood (2024) 144 (Supplement 1): 4283.
https://doi.org/10.1182/blood-2024-206872
Published: 2024
Journal Articles

Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study

Guopan Yu, Yu Zhang, Hua Jin, Zhao Yin, Guangyang Weng, Sijian Yu, Na Xu, Xin Du, Dongjun Lin, Jie Xiao, Zhiqiang Sun, Hongyu Zhang, Xinquan Liang, Ziwen Guo, Weihua Zhao, Min Dai, Xuejie Jiang, Li Xuan, Pengcheng Shi
Journal: Blood
Blood (2023) 142 (Supplement 1): 4262.
https://doi.org/10.1182/blood-2023-182847
Published: 2023
Journal Articles

Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia

Guopan Yu, Zhao Yin, Hua Jin, Sijian Yu, Yuhua Li, Danian Nie, Ziwen Guo, Zhiqiang Sun, Qingxiang Meng, Weihua Zhao, Dongjun Lin, Na Xu, Yu Zhang
Journal: Blood
Blood (2022) 140 (Supplement 1): 11796.
https://doi.org/10.1182/blood-2022-168004
Published: 2022
Journal Articles

Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

Guangyang Weng, Yu Zhang, Guopan Yu, Na Xu, Zhiqiang Sun, Dongjun Lin, Xinquan Liang, Lan Deng, Jie Xiao, Hongyu Zhang, Ziwen Guo, Hua Jin, Xin Du, Qifa Liu
Journal: Blood
Blood (2022) 140 (Supplement 1): 2025–2026.
https://doi.org/10.1182/blood-2022-158762
Published: 2022
Journal Articles

Ixazomib Based Maintenance Therapy for the Patients with Newly Diagnosed Multiple Myeloma in Real-World Practice

Liye Zhong, Yongqiang Wei, Baohong Ping, Xin Li, Hongling Peng, Yongqain Li, Yuyang Tian, Zelin Liu, Jun Luo, Yongzhong Su, Haifei Chen, Yanjuan He, Hongliang Li, Congming Wu, Zhiqiang Sun, Keqian Shi, Xiaoliang Li, Qing Zhang, Guoyu Hu, Gang Huang, Zhenqian Huang, Weida Wang, Zhongjun Xia
Journal: Blood
Blood (2021) 138 (Supplement 1): 2718.
https://doi.org/10.1182/blood-2021-149058
Published: 2021